

Soluble urokinase-type plasminogen activator receptor represents exercise tolerance and predicts adverse cardiac events in patients with heart failure

Hirotoishi Ishikawa, Yasuhiro Izumiya, Atsushi Shibata, Yoshitaka Ichikawa, Takehiro Yamaguchi, Yumi Yamaguchi, Ryoko Kitada, Shinichi Iwata, Shoichi Ehara, Shuhei Tomita, Akihisa Hanatani, Minoru Yoshiyama

Citation	Heart and Vessels. 35(5); 681–688
Published	2019-11-18
Issue Date	2020-05
Type	Journal Article
Textversion	Author
Rights	This is a post-peer-review, pre-copyedit version of an article published in Heart Vessels. The final authenticated version is available online at: https://doi.org/10.1007/s00380-019-01538-3 . See Springer Nature terms of reuse. https://www.springer.com/gp/open-access/publication-policies/aam-terms-of-use .
DOI	10.1007/s00380-019-01538-3

Self-Archiving by Author(s)
Placed on: Osaka City University

1 **Soluble urokinase type plasminogen activator receptor represents exercise tolerance**
2 **and predicts adverse cardiac events in patients with heart failure**

3

4 Hirotoishi Ishikawa¹, MD; Yasuhiro Izumiya¹, MD, PhD; Atsushi Shibata¹, MD, PhD;

5 Yoshitaka Ichikawa¹, MD; Takehiro Yamaguchi², MD, PhD; Yumi Yamaguchi¹, MD;

6 Ryoko Kitada¹, MD, PhD; Shinichi Iwata¹, MD, PhD; Shoichi Ehara¹, MD, PhD; Shuhei

7 Tomita², MD, PhD; Akihisa Hanatani¹, MD, PhD; Minoru Yoshiyama¹, MD, PhD

8

9 **Institution:** ¹Department of Cardiovascular medicine and ²Department of Pharmacology,

10 Osaka City University Graduate School of Medicine, Osaka, Japan

11 **Address for correspondence:**

12 Yasuhiro Izumiya, MD, PhD, FACC, FAHA

13 Department of Cardiovascular Medicine

14 Osaka City University Graduate School of Medicine

15 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8586, Japan

16 Tel: +81-6-6645-3801. Fax: +81-6-6646-6808

17 Email: izumiya.yasuhiro@med.osaka-cu.ac.jp

18

1 **Abstract**

2 **Background:** Soluble urokinase type plasminogen activator receptor (suPAR) is a
3 membrane binding protein that is released into the blood stream by immune activation.
4 Recent reports suggest that circulating suPAR levels are associated with adverse
5 cardiovascular outcomes. Exercise tolerance is an independent predictor of prognosis in
6 patients with heart failure (HF); however, the relationship between serum suPAR level
7 and exercise tolerance is unclear.

8 **Methods and results:** We prospectively enrolled 94 patients who were hospitalized for
9 worsening of HF. All patients underwent a symptom-limited cardiopulmonary exercise
10 test to evaluate exercise tolerance. The median value of serum suPAR was 4848 pg/ml.
11 During follow-up, 44 patients (47%) were admitted for all-cause mortality and re-
12 hospitalization for HF. Median serum suPAR was significantly higher in the patients with
13 cardiac events than in the patients with non-event group. Patients were divided into 2
14 groups according to circulating suPAR levels. Kaplan-Meier analysis demonstrated that
15 adverse cardiac events were significantly higher in the high suPAR group (log-rank
16 $p=0.023$). Multivariate analysis revealed that suPAR was independently correlated with
17 the parameters of exercise tolerance such as anaerobic threshold ($p=0.007$) and peak
18 oxygen uptake ($p=0.005$).

19 **Conclusion:** suPAR levels predicted adverse cardiac events and independently correlated
20 with the parameters of exercise tolerance. suPAR could be a useful surrogate biomarker
21 of exercise tolerance in patients with HF.

22

23 **Key Words:** Soluble urokinase type plasminogen activator receptor; Exercise tolerance;
24 Heart failure

1 **Introduction**

2 Soluble urokinase type plasminogen activator receptor (suPAR) is
3 glycosylphosphatidylinositol-anchored glycoprotein that is expressed mainly in
4 inflammatory cells [1, 2]. SuPAR is proteolytically cleaved and released into the blood
5 stream in response to various inflammatory stimuli [3, 4]. It has been suggested that
6 activated neutrophils release suPAR, and it is supposed that this release from neutrophils
7 contributes to recruitment of monocytes to sites of active inflammation [5, 6]. Because a
8 part of suPAR is released into the circulation by proteolytic shedding, its circulating
9 levels are expected to be a potential biomarker for low-grade inflammation [7], and
10 suPAR may play an important role in various disease. For instance, previous reports
11 suggested that circulating suPAR levels are independently associated with severity of
12 chronic kidney disease[8], and suPAR levels are specifically elevated in patients with
13 focal segmental glomerulosclerosis (FSGS), and have an important role in the
14 pathogenesis of FSGS[9]. In the cardiovascular field, previous studies have reported that
15 circulating suPAR levels are associated with an increased incidence of atherosclerosis
16 and coronary artery disease [10, 11]. Moreover, Koller et al. recently reported that suPAR
17 is a strong and independent predictor of mortality in patients with heart failure (HF) [12].
18 These data indicate that circulating suPAR could be used as a biomarker to reflect low-
19 grade chronic inflammatory status and various diseases.

20 HF is a common syndrome that develops from various comorbidities, and it is
21 anticipated that the number of patients will increase with the growth of an aging society
22 [13, 14]. It has been demonstrated that exercise capacity is an independent prognostic
23 indicator for patients with HF [15, 16]. To date, however, there are few biomarkers that
24 reflect exercise tolerance in these patients. It was reported that circulating suPAR levels

1 affected acute or chronic exercise [^{17, 18}]. In addition, a recent study showed that suPAR
2 levels even reflect lifestyles, including physical activity, in a cardiovascularly healthy
3 cohort [¹⁹]. However, another study reported that long-term physical activity per se does
4 not appear to have an effect on circulating suPAR levels [²⁰].

5 Given that serum suPAR levels reflect the prognosis of HF, we hypothesize that it
6 could be used as a surrogate biomarker of the exercise tolerance. In this study, we
7 measured serum suPAR levels in patients with HF and determined its significance in the
8 assessment of exercise capacity, disease severity, and prognosis.

1 **Methods**

2 Study population

3 We enrolled 94 consecutive patients who were hospitalized for worsening HF at
4 Osaka City University Hospital between July 2013 and March 2015. To diagnose HF, all
5 patients had to meet the diagnosis with two major criteria or one major criterion in
6 conjunction with two minor Framingham criteria [21]. The patients who met the following
7 conditions were excluded; (1) experienced acute coronary syndrome within the preceding
8 30 days; (2) underwent open heart surgery within the preceding 3 months; (3) underwent
9 percutaneous coronary angioplasty or cardiac resynchronization therapy during cardiac
10 rehabilitation; (4) had symptomatic valvular heart disease; (5) had end-stage renal failure
11 (estimated glomerular filtration rate (eGFR) < 15 ml/min/1.73 m²); (6) had chronic
12 inflammatory disease; (7) could not perform cardiopulmonary exercise testing (CPX)
13 owing to musculoskeletal problems or paralysis; and (8) was unwilling to provide
14 informed consent.

15

16 Follow-up

17 The endpoints of this study were a composite of all cause mortality and
18 unplanned admission to hospital for worsening HF. Patients were followed up for a
19 median of 796 days (interquartile range (IQR) 427-1076 days).

20 Clinical characteristics, laboratory, and echocardiogram data were collected
21 from the patients' medical records at the time of enrollment. An echocardiographic
22 examination was performed by at least two experienced technicians in a blinded manner,
23 and the ejection fraction (EF) was determined by the modified Simpson's method.

24 The study protocol conformed to the principles of the Declaration of Helsinki

1 and was conducted after approval of the ethics committee of our institution (approval
2 number 2569) and, written informed consent was obtained from each patient.

3 4 Cardiopulmonary exercise test

5 All patients underwent a symptom-limited CPX before discharge. The CPX was
6 performed using a cycle ergometer (Strength Ergo 8; Fukuda Denshi, Tokyo, Japan) with
7 a ramp protocol. The ramp protocol is characterized by a gradual increase in work rate,
8 which is evenly distributed within each minute of the exercise phase [22]. In this study,
9 the ramp protocol started at 0 or 10 W for a 4-min warm-up and was followed by an
10 incrementally increasing work rate of 10 W every minute (this increased the work rate by
11 1 W every 6 s) up to the patient's limit. The electrocardiogram was monitored
12 continuously and blood pressure was recorded every minute before, during, and after
13 exercise (ML-9000; Fukuda Denshi, Tokyo, Japan). Expired gas analysis was performed
14 with the breath-by-breath method using an expired gas analyzer (Cpex-1; Inter Reha,
15 Tokyo, Japan). The following parameters were measured and calculated: peak oxygen
16 uptake (peak VO_2), minute ventilation (VE), and carbon dioxide production (VCO_2). Peak
17 VO_2 was defined as the highest VO_2 value achieved at peak exercise. The peak respiratory
18 exchange ratio (carbon dioxide production/ VO_2) was used to determine maximal effort.
19 The anaerobic threshold (AT) was determined using the V-slope method. The slope of the
20 relationship between VE and VCO_2 (VE/ VCO_2 slope) as a marker of ventilator
21 inefficiency was obtained. The oxygen uptake efficiency slope (OUES), as an indicator
22 of cardiopulmonary functional reserve, was obtained from the relationship between VO_2
23 and the logarithmic change in VE [23].

24

1 Laboratory analysis

2 Blood samples were obtained by venipuncture at the time of hospital admission.
3 Standard laboratory measurements were determined from fresh samples. Circulating
4 levels of serum creatinine, high-sensitivity C-reactive protein (hs-CRP), high-sensitivity
5 troponin T (hs-TnT), and B-type natriuretic peptide (BNP) were analyzed using certified
6 methods in the Department of Clinical Laboratory, Osaka City University. eGFR was
7 calculated using the modified IDMS-MDRD study equation [24]: eGFR (ml/min/1.73 m²)
8 = 194 × (serum creatinine)^{-1.094} × (age)^{-0.287} × (0.739, when female).

9 Blood samples for analysis of suPAR were collected before CPX. After
10 centrifugation at 4 °C and 3000 rpm for 15 min, serum samples were stored at -80 °C
11 until analysis. Serum concentrations of suPAR were determined from thawed samples,
12 using commercially available enzyme-linked immunosorbent assay (ELISA) kits (R&D
13 System, Minneapolis, MN, USA).

14

15 Statistical analysis

16 Continuous variables were presented as mean ± standard deviation (SD) or
17 median with inter-quartile range (IQR) for non-normally distributed variables.
18 Categorical variables were presented as number (percent). Receiver operating
19 characteristic (ROC) curves were performed to detect the optimal cutoff point of suPAR
20 to estimate the event free rate. To compare each parameter between the low and high
21 suPAR groups, we used an unpaired t test, or the Wilcoxon-Mann-Whitney test or Fisher's
22 exact test for categorical variables.

23 The Spearman correlation coefficient between suPAR and each continuous
24 variable was calculated. The Kaplan-Meier curves were constructed for the times to

1 events, which was death or to hospitalization for worsening HF, and the log-rank test was
2 used for initial comparison. Multivariate linear regression analysis was used to adjust for
3 clinical covariates, such as age, hemoglobin, and eGFR. There were reports showing that
4 age, eGFR are strongly related to serum suPAR level [12, 25], we analyzed with these
5 factors and AT (model 1) or peak VO₂ (model 2). Because AT and peak VO₂ have an
6 internal correlation[26], these parameters were needed to be analyzed separately.

7 All data were analyzed using R software package (version 3.2.1; R Foundation
8 for Statistical Computing, Vienna, Austria). A value of $P < 0.05$ was considered
9 statistically significant.

1 **Results**

2 The clinical characteristics of all study participants are presented in Table 1. The
3 subjects consisted of patients with ischemic and non-ischemic HF (17% and 83%,
4 respectively). The mean age of the patients was 68 years, and mean EF was 38.4%.

5 In this population, the median serum suPAR level was 4848.5 pg/ml (IQR: 3261.2
6 to 6589.0 pg/ml). Median serum suPAR was significantly higher in the patients with
7 cardiac events (5530.5 pg/ml) than in the patients with non-event group (4590.0 pg/ml,
8 $P=0.047$; Figure 1). Based on the ROC curve, the optimal cutoff value of the suPAR
9 level to detect mortality and rehospitalization was determined to be 4170 pg/ml with 79%
10 sensitivity and 49% specificity (area under the curve 0.64). Using the value, all patients
11 were divided into 2 groups (Table 1): high suPAR group (median, 6170.0 pg/ml) and low
12 suPAR group (median, 2953.6 pg/ml). The high suPAR group was older than the low
13 suPAR group. In addition, the high suPAR patients more likely suffered from renal
14 dysfunction. On echocardiography, EF was not significantly different between the 2
15 groups. There was no significance difference in cardiovascular medication between the
16 high and low groups.

17 During follow-up, 44 of the 94 patients died or needed to be re-hospitalized because
18 of worsening HF (cardiac death, $n=3$, all cause death, $n=8$, rehospitalization for HF, $n=36$).
19 As shown in Figure 2, Kaplan-Meier analysis revealed that the high suPAR group had a
20 significantly higher probability of death or re-hospitalization (log-rank test, $p=0.023$).

21 CPX parameters were compared between the high and low suPAR groups (Table
22 2). The values of AT and peak VO_2 were significantly higher in the low suPAR group
23 compared with the high suPAR group (Figure 3). Minimum VE/VCO_2 was lower and
24 OUES was higher in the low suPAR group than in the high group. Other parameters such

1 as the VE/VCO₂ slope were not different between the 2 groups.

2 We evaluated the correlation between serum suPAR levels and each continuous
3 variable, including AT and peak VO₂ (Table 3). Spearman correlation coefficient analysis
4 showed a statistically significant positive correlation between serum suPAR levels and
5 age, and a negative correlation between suPAR and hemoglobin, eGFR, AT, and VO₂. As
6 shown in Table 4, multivariate analysis revealed that suPAR was independently correlated
7 with exercise tolerance parameters such as peak VO₂ (p=0.007) and AT (p=0.005).

8

1 **Discussion**

2 In the present study, we showed an association between serum suPAR levels and
3 exercise capacity in patients with HF. The present study reported the following findings:
4 (1) the prevalence of adverse cardiac events was significantly higher in the high suPAR
5 group, (2) serum suPAR levels were inversely correlated with the exercise tolerance
6 parameters such as AT and peak VO₂. Together, these findings indicate that circulating
7 suPAR is a potentially useful surrogate marker of exercise tolerance in patients with HF,
8 and could thus predict the prognosis in these patients.

9 Exercise tolerance is an established independent prognostic factor for patients with
10 HF [15, 16]. It has been shown that some cardio-protective biomarkers such as brain derived
11 neurotrophic factor (BDNF) [27] correlate with aerobic exercise performance in patients
12 with HF. On the other hand, experimental rodent HF models showed that pro-
13 inflammatory cytokines such as tumor necrosis factor α (TNF- α) and interleukin-6 (IL-
14 6) caused skeletal muscle exhaustion and accelerate sarcopenia, which ultimately reduced
15 exercise tolerance [28]. These inflammatory cytokines are regarded as a surrogate
16 biomarkers of exercise tolerance in patients with HF [29-31]. Because suPAR has been
17 reported as an inflammatory biomarker [7], we hypothesized that the serum suPAR level
18 reflects exercise capacity in patients with HF and demonstrated that its level
19 independently correlated with the exercise tolerance parameters.

20 There were some controversial results showing the relationship between circulating
21 suPAR levels and exercise ability [17, 18, 32]. In fact, long-term physical activity per se does
22 not appear to affect circulating suPAR levels [20]. The reason was thought to be that the
23 methods of evaluating exercise capacity were different. Most previous studies
24 investigating circulating suPAR level and exercise tolerance employed acute exercise as

1 the mode of exercise, so it was difficult to evaluate exercise capacity quantitatively. In
2 contrast, in the present study, we evaluated exercise capacity in all patients using a precise
3 CPX test, and demonstrated a significant negative correlation between suPAR and AT and,
4 peak VO₂. The reason for no correlation existing between suPAR and the VE/VO₂ slope
5 may be explained as the CPX measurement including not only cardiopulmonary function,
6 but also respiratory muscle, skeletal muscle, and sympathetic function. Therefore, the
7 specific value of the ventilation perfusion mismatch was not unambiguously linked.

8 Expression of suPAR is strongly activated during inflammation, immune responses,
9 tissue injury, and wound healing [33]. Additionally, suPAR is thought to be involved in
10 pathophysiological pathways that are associated with atherosclerosis in a different
11 manner from inflammatory processes [33]. We speculate that these mechanisms might be
12 the cause of suPAR reflecting not only chronic inflammation, but also exercise tolerance
13 at the same time. However, the reason why suPAR levels are elevated in patients with
14 heart failure remains unclear. Recently, Fujisawa et al. reported that serum suPAR levels
15 were associated with diastolic dysfunction independent of confounding factors in patients
16 with heart failure with preserved EF [34]. Because suPAR is involved in many pathways,
17 further investigations are required to determine the mechanism by which suPAR affects
18 development of heart failure.

19 There were several limitations in the present study. First, this was a single center
20 study and included only a small number of cases. Second, our cohort included several
21 etiologies, such as ischemic heart disease, dilated cardiomyopathy, and secondary
22 cardiomyopathy and arrhythmia. Although the precise cellular source of suPAR could not
23 be determined in this study, our data suggest that suPAR could be used as a surrogate
24 marker of exercise tolerance in patients with HF. Further studies are needed to assess the

1 value of suPAR in a large number of patients.

2 In conclusion, suPAR level predicted adverse cardiac events and independently
3 correlated with exercise tolerance parameters. SuPAR could be a useful surrogate
4 biomarker of the exercise tolerance in patients with HF.

1 **Conflict of interest: The authors declare that they have no conflict of interest.**

2

3 **Acknowledgements:**

4 This work was supported in part by The Nakatomi Foundation and The Mitsui

5 Sumitomo Insurance Welfare Foundation to Y.I. The authors would like to acknowledge

6 the support of the research support platform of Osaka City University Graduate School

7 of Medicine for special technical assistance.

1 **References**

- 2 1. Huang M, Mazar AP, Parry G, Higazi AA, Kuo A, Cines DB (2005)
3 Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-
4 terminal fragment (1-143). *Acta Crystallogr D Biol Crystallogr* 61:697-700.
- 5 2. Thuno M, Macho B, Eugen-Olsen J (2009) suPAR: the molecular crystal ball.
6 *Dis Markers* 27:157-172.
- 7 3. Blasi F, Carmeliet P (2002) uPAR: a versatile signalling orchestrator. *Nat Rev*
8 *Mol Cell Biol* 3:932-943.
- 9 4. Masucci MT, Pedersen N, Blasi F (1991) A soluble, ligand binding mutant of the
10 human urokinase plasminogen activator receptor. *J Biol Chem* 266:8655-8658.
- 11 5. Pliyev BK (2009) Activated human neutrophils rapidly release the
12 chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor
13 (uPAR/CD87). *Mol Cell Biochem* 321:111-122.
- 14 6. Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M, Blasi
15 F (2002) The fibrinolytic receptor for urokinase activates the G protein-coupled
16 chemotactic receptor FPRL1/LXA4R. *Proc Natl Acad Sci U S A* 99:1359-1364.
- 17 7. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde
18 A, Petersen J, Pielak T, Møller LN, Jeppesen J, Lyngbaek S, Fenger M, Olsen MH,
19 Hildebrandt PR, Borch-Johnsen K, Jørgensen T, Haugaard SB (2010) Circulating soluble
20 urokinase plasminogen activator receptor predicts cancer, cardiovascular disease,
21 diabetes and mortality in the general population. *J Intern Med* 268:296-308.
- 22 8. Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, Altintas MM,
23 Wei C, Hotton AL, French AL, Sperling LS, Lerakis S, Quyyumi AA, Reiser J (2015)
24 Soluble Urokinase Receptor and Chronic Kidney Disease. *N Engl J Med* 373:1916-1925.

- 1 9. Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, McMahan JL,
2 Radeva M, Heil KM, Trautmann A, Anarat A, Emre S, Ghiggeri GM, Ozaltin F, Haffner
3 D, Gipson DS, Kaskel F, Fischer DC, Schaefer F, Reiser J, Consortia PaFCS (2012)
4 Circulating suPAR in two cohorts of primary FSGS. *J Am Soc Nephrol* 23:2051-2059.
- 5 10. Dalos D, Spinka G, Schneider M, Wernly B, Paar V, Hoppe U, Litschauer B,
6 Strametz-Juranek J, Sponder M (2019) New Cardiovascular Biomarkers in Ischemic
7 Heart Disease-GDF-15, A Probable Predictor for Ejection Fraction. *J Clin Med* 8:
8 DOI:10.3390/jcm8070924
- 9 11. Persson M, Östling G, Smith G, Hamrefors V, Melander O, Hedblad B, Engström
10 G (2014) Soluble urokinase plasminogen activator receptor: a risk factor for carotid
11 plaque, stroke, and coronary artery disease *Stroke* 45:18-23
- 12 12. Koller L, Stojkovic S, Richter B, Sulzgruber P, Potolidis C, Liebhart F, Mortl D,
13 Berger R, Goliash G, Wojta J, Hulsmann M, Niessner A (2017) Soluble Urokinase-Type
14 Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic
15 Heart Failure. *JACC Heart Fail* 5:268-277.
- 16 13. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn
17 BP, Jacobsen SJ (2004) Trends in heart failure incidence and survival in a community-
18 based population. *JAMA* 292:344-350.
- 19 14. Miura Y, Fukumoto Y, Miura T, Shimada K, Asakura M, Kadokami T, Ando S,
20 Miyata S, Sakata Y, Daida H, Matsuzaki M, Yasuda S, Kitakaze M, Shimokawa H (2013)
21 Impact of physical activity on cardiovascular events in patients with chronic heart failure.
22 A multicenter prospective cohort study. *Circ J* 77:2963-2972.
- 23 15. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH, Wilson JR (1991)
24 Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation

- 1 in ambulatory patients with heart failure. *Circulation* 83:778-786.
- 2 16. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow
3 GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi
4 FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson
5 LW, Tang WH, Tsai EJ, Wilkoff BL (2013) 2013 ACCF/AHA guideline for the
6 management of heart failure: executive summary: a report of the American College of
7 Cardiology Foundation/American Heart Association Task Force on practice guidelines.
8 *Circulation* 128:1810-1852.
- 9 17. Gustafsson A, Ventorp F, Wisén AG, Ohlsson L, Ljunggren L, Westrin Å. (2017)
10 Effects of Acute Exercise on Circulating Soluble Form of the Urokinase Receptor in
11 Patients With Major Depressive Disorder. *Biomark Insights* 12:1177271917704193.
- 12 18. Rohde C, Polcwiartek C, Andersen E, Vang T, Nielsen J (2018) Effect of a
13 physical activity intervention on suPAR levels: A randomized controlled trial. *J Sci Med
14 Sport* 21:286-290.
- 15 19. Haupt TH, Rasmussen LJH, Kallemose T, Ladelund S, Andersen O, Pisinger C,
16 Eugen-Olsen J (2019) Healthy lifestyles reduce suPAR and mortality in a Danish general
17 population study. *Immun Ageing* 16:1.
- 18 20. Sponder M, Lichtenauer M, Wernly B, Paar V, Hoppe U, Emich M, Fritzer-
19 Szekeres M, Litschauer B, Strametz-Juranek J (2019) Serum heart-type fatty acid-binding
20 protein decreases and soluble isoform of suppression of tumorigenicity 2 increases
21 significantly by long-term physical activity. *J Investig Med* 67:833-840
- 22 21. McKee PA, Castelli WP, McNamara PM, Kannel WB (1971) The natural history
23 of congestive heart failure: the Framingham study. *N Engl J Med* 285:1441-1446.
- 24 22. Guazzi M, Arena R, Halle M, Piepoli M. F, Myers J, Lavie C. J (2016) 2016

- 1 Focused Update: Clinical Recommendations for Cardiopulmonary Exercise Testing Data
2 Assessment in Specific Patient Populations *Circulation* 133:e694-711
- 3 23. Baba R, Nagashima M, Goto M, Nagano Y, Yokota M, Tauchi N, Nishibata K
4 (1996) Oxygen uptake efficiency slope: a new index of cardiorespiratory functional
5 reserve derived from the relation between oxygen uptake and minute ventilation during
6 incremental exercise. *J Am Coll Cardiol* 28:1567-1572.
- 7 24. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino
8 Y, Yokoyama H, Hishida A, GFR CdtJefe (2009) Revised equations for estimated GFR
9 from serum creatinine in Japan. *Am J Kidney Dis* 53:982-992.
- 10 25. Westin O, Rasmussen LJH, Andersen O, Buch E, Olsen JE, Friberg J (2018)
11 Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Predictor of Incident
12 Atrial Fibrillation. *J Atr Fibrillation* 10:1801.
- 13 26. Cardiology WGoCREPaWGoHFotESo (2001) Recommendations for exercise
14 testing in chronic heart failure patients. *Eur Heart J* 22:37-45.
- 15 27. Shibata A, Hanatani A, Izumi Y, Kitada R, Iwata S, Yoshiyama M (2018) Serum
16 brain-derived neurotrophic factor level and exercise tolerance complement each other in
17 predicting the prognosis of patients with heart failure. *Heart Vessels* 33:1325-1333.
- 18 28. Janssen SP, Gayan-Ramirez G, Van den Bergh A, Herijgers P, Maes K, Verbeken
19 E, Decramer M (2005) Interleukin-6 causes myocardial failure and skeletal muscle
20 atrophy in rats. *Circulation* 111:996-1005.
- 21 29. Kalogeropoulos A, Georgiopoulou V, Psaty BM, Rodondi N, Smith AL, Harrison
22 DG, Liu Y, Hoffmann U, Bauer DC, Newman AB, Kritchevsky SB, Harris TB, Butler J,
23 Investigators HAS (2010) Inflammatory markers and incident heart failure risk in older
24 adults: the Health ABC (Health, Aging, and Body Composition) study. *J Am Coll Cardiol*

- 1 55:2129-2137.
- 2 30. Mikkelsen UR, Couppé C, Karlsen A, Grosset JF, Schjerling P, Mackey AL,
3 Klausen HH, Magnusson SP, Kjær M (2013) Life-long endurance exercise in humans:
4 circulating levels of inflammatory markers and leg muscle size. *Mech Ageing Dev*
5 134:531-540.
- 6 31. Palacios G, Pedrero-Chamizo R, Palacios N, Maroto-Sánchez B, Aznar S,
7 González-Gross M, Group ES (2015) Biomarkers of physical activity and exercise. *Nutr*
8 *Hosp* 31 Suppl 3:237-244.
- 9 32. Sanchis-Gomar F, Bonaguri C, Pareja-Galeano H, Gomez-Cabrera MC, Candel
10 J, Viña J, Lippi G (2013) Effects of acute exercise and allopurinol administration on
11 soluble urokinase plasminogen activator receptor (suPAR). *Clin Lab* 59:207-210.
- 12 33. Smith H. W, Marshall C. J, (2010) Regulation of cell signalling by uPAR *Nat*
13 *Rev Mol Cell Biol* 11:23-36
- 14 34. Fujisaka T, Fujita S. I, Maeda D, Shibata K, Takahashi H, Morita H, Takeda Y,
15 Ito T, Sohmiya K, Hoshiga M, Ishizaka N (2017) Association between suPAR and cardiac
16 diastolic dysfunction among patients with preserved ejection fraction *Heart Vessels* 32:
17 1327-1336
- 18

1 **Figure Legends**

2 **Figure 1.** Serum soluble urokinase plasminogen activator receptor (suPAR) level in
3 patients with clinical events (mortality or re-hospitalization of worsening HF) (n=44)
4 and patients with no clinical event (n=50).

5

6 **Figure 2.** Kaplan-Meier analysis for the probability of death and rehospitalization
7 because of heart failure in patients with high (n=55) and low suPAR (n=39).

8 Primary events were significantly higher in the high suPAR group than in the low group
9 (log-rank p=0.023).

10

11 **Figure3.** Comparison in AT and peak VO₂ between high and low suPAR group.

Table 1. Baseline characteristics of the patients				
	Total n=94	Low suPAR group (≤4170 pg/ml) n=39	High suPAR group (> 4170 pg/ml) n=55	P
Age (years)	68.0±14.5	63.0±15.2	71.5±13.0	0.003
Male (%)	60 (63.8)	28 (73.7)	32 (56.1)	0.18
Current Smoking (%)	11 (11.7)	5 (10.5)	6 (12.3)	0.97
BMI (kg/m ²)	22.2±4.1	21.7	21.9	0.843
SBP (mmHg)	108.9±19.1	110.5±19.0	107.8±19.2	0.49
Heart rate (bpm)	75.1±13.6	74.1±13.4	75.8±13.9	0.56
Comorbidity				
HT (%)	42 (44.7)	18 (47.3)	24 (42.1)	0.98
DM (%)	28 (29.8)	9 (23.7)	19 (33.3)	0.33
DLP (%)	42 (44.7)	15 (39.4)	27 (49.1)	0.42
Af (%)	36 (38.3)	10 (25.6)	26 (47.3)	0.032
Ischemic HF (%)	16 (17.0)	6 (15.8)	10 (17.5)	0.94
Baseline use of medications				
ACE inhibitor or ARB (%)	59 (62.8)	29 (74.4)	30 (54.5)	0.055
β-blocker (%)	75 (79.8)	32 (82.1)	43 (78.2)	0.80
Aldosterone inhibitor (%)	44 (46.8)	21 (53.8)	23 (41.8)	0.30
Statin (%)	38 (40.4)	20 (51.3)	18 (32.7)	0.60
Baseline use of devices				
Pacemaker (%)	8 (8.5)	0	8 (14.5)	0.059
ICD (%)	4 (4.3)	0	4 (7.2)	0.14
CRT (%)	3 (3.2)	1 (2.5)	2 (3.6)	1.00
Echocardiogram				
LVEDD (mm)	55.2±9.8	57.7±10.9	53.4±8.5	0.037
LVESD (mm)	43.0±13.1	46.4±14.4	40.6±11.5	0.032
IVS (mm)	8.9±2.0	8.5±2.3	9.2±1.7	0.12
LAD (mm)	45.8±7.8	43.9±6.4	47.1± 8.5	0.052
LVEF (%)	38.4±14.8	35.9±15.7	40.1±13.9	0.14
DCT (msec)	177.6±62.5	182.1±66.9	174.2±59.4	0.57
E/e' ratio	20.5±10.1	19.3±11.8	21.5±8.7	0.35
TRPG (mmHg)	31.2±13.7	31.6±18.7	31.0±9.3	0.85
Laboratory data				
Hemoglobin (g/dl)	12.5±2.3	13.6±2.2	11.7±2.0	<0.001
Serum Sodium (mEq/l)	139.5±2.9	140 (137-141)	140 (138-142)	0.34
eGFR (ml/min/1.73 m ²)	50.6±20.8	58.6±12.8	44.8±23.5	0.001
BNP (pg/ml)	452.1 (197.7-827.0)	464.1 (208.7-806.0)	450.5 (198.8-817.1)	0.78
hs-CRP (g/dl)	0.23 (0.11-0.51)	0.13 (0.10-0.36)	0.29 (0.155-0.52)	0.068
hs-Troponin T (ng/ml)	0.017 (0.010-0.042)	0.015 (0.010-0.029)	0.024 (0.010-0.048)	0.074

SuPAR (pg/ml)	4848.5 (3261.2-6589.0)	2953.6 (2398.4-3609.6)	6170.0 (5220.2-7324.0)	<0.001
------------------	---------------------------	---------------------------	---------------------------	------------------

Values are presented mean \pm standard deviation, median (inter-quartile range), or n (%) BMI; body mass index, SBP; systolic blood pressure, HT; hypertension, DM; diabetes mellitus, DLP; dyslipidemia, Af; atrial fibrillation, HF; heart failure LVEF; left ventricular ejection fraction, ACE; angiotensin convert enzyme, ARB; angiotensin type II receptor blocker, ICD; implantable cardioverter-defibrillator, CRT; cardiac resynchronization therapy, LVEDD; left ventricular end-diastolic diameter, LVESD; left ventricular end-systolic diameter, IVS; interventricular septum, LAD; left atrium diameter, DCT; deceleration time, TRPG; tricuspid regurgitation pressure gradient, BNP; B-type natriuretic peptide, hs-CRP; high-sensitivity C-reactive protein, eGFR; estimated glomerular filtration

Table 2. Cardiopulmonary exercise test data				
	Total n=94	Low suPAR group (\leq 4170 pg/ml) n=39	High suPAR group ($>$ 4170 pg/ml) n=55	P
Peak work rate (watts)	56.7 (40-70)	63.0 (45.5-75.0)	51.0 (39.0-62.0)	0.024
Anaerobic threshold (mg/kg/min)	12.8 (11.5-14.9)	14.2 (11.9- 15.4)	12.4 (11.1-14.2)	0.009
peakVO ₂ (mg/kg/min)	17.1 (14.9-20.6)	19.3 (16.1-21.3)	15.7 (13.4-18.7)	0.001
Peak O ₂ pulse (ml/beats)	8.54 (7.10-10.23)	8.99 (8.07-10.98)	8.15 (6.59-9.42)	0.133
VE/VCO ₂ slope	32.4 (28.0-36.5)	31.6 (27.1-34.4)	33.6 (28.7-38.4)	0.110
Minimum VE/VCO ₂	26.4 (24.0-30.5)	25.4 (22.6-27.1)	27.9 (25.0-31.4)	0.038
Δ HR/ Δ WR (beats/min/watt)	0.51 (0.33-0.64)	0.52(0.31-0.70)	0.46(0.36-0.62)	0.798
OUES	1352 (1053-1763)	1134.5 (1479.0-1950.5)	939.3 (475.0-1192.5)	0.011

Values are presented as median (inter-quartile range).

VO₂; oxygen uptake, VE; ventilatory equivalent, VCO₂; carbon dioxide output, HR; heart rate, WR; work rate, OUES; oxygen uptake efficiency slope

Table 3. Spearman correlation coefficient analysis between serum suPAR levels and each continuous variable

	Spearman r	P
Age (years)	0.226	0.028
eGFR (ml/min/1.73m ²)	-0.422	< 0.001
BNP (pg/ml)	0.053	0.614
hs-CRP (mg/dl)	0.198	0.055
BMI (kg/m ²)	-0.023	0.824
Hemoglobin (g/dl)	-0.373	< 0.001
LVEF (%)	0.089	0.392
AT (mg/kg/min)	-0.348	< 0.001
Peak VO ₂ (mg/kg/min)	-0.367	< 0.001

eGFR; estimated glomerular filtration, BNP; B-type natriuretic peptide, hs-CRP; high-sensitivity C-reactive protein, BMI; body mass index LVEF; left ventricular ejection fraction, AT; anaerobic threshold

Table 4. Factors associated with ln (suPAR)				
Factors	Multivariate analysis model 1		Multivariate analysis model 2	
	B (95% CI)	P	B (95% CI)	P
Age (years)	-0.002 (-0.005 to 0.001)	0.161	-0.003 (-0.006 to 0.001)	0.099
eGFR (ml/min/1.73 m ²)	-0.003 (-0.005 to -0.001)	0.002	-0.021 (-0.005 to -0.001)	0.003
Hb (g/dl)	-0.021 (-0.039 to -0.002)	0.025	-0.021 (-0.039 to 0.002)	0.026
AT(mg/kg/min)	-0.020 (-0.035 to -0.006)	0.007	Not selected	
Peak VO ₂ (mg/kg/min)	Not selected		-0.014 (-0.024 to -0.004)	0.005

CI; confidence interval.

Hb; Hemoglobin

Other abbreviations as in Table 1.

Figure 1




Figure 2





Figure 3

(A)



(B)

